PMID- 27762125
OWN - NLM
STAT- MEDLINE
DCOM- 20190503
LR  - 20190503
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 64
IP  - 8
DP  - 2016 Aug
TI  - Bortezomib Based Chemotherapy for Light Chain Deposition Disease.
PG  - 97-98
AB  - Light chain deposition disease (LCDD) is a rare systemic disorder in which 
      monoclonal light chains are abnormally secreted due to clonal proliferation of 
      plasma cells and get deposited in various organs; the kidneys being the common 
      one to be affected leading to renal failure. Advocated therapeutic options 
      include chemotherapy with alkylating agents and steroids, High-Dose Melphalan 
      (HDM) with Autologous Stem Cell Transplantation. Recently, Bortezomib has proven 
      to be a novel therapeutic option in these patients when combined with 
      dexamethasone. Here, we report a patient who presented with acute renal failure, 
      was diagnosed to have LCDD and treated with bortezomib and dexamethasone.
CI  - (c) Journal of the Association of Physicians of India 2011.
FAU - Kandakumar, Vignesh
AU  - Kandakumar V
AD  - Assistant Professor, Department of Medical Oncology.
FAU - Nagalapuram, Vishnu
AU  - Nagalapuram V
AD  - Final Year MBBS Student.
FAU - Menon, Sujaya
AU  - Menon S
AD  - Professor, Department of General Medicine, PSG Institute of Medical Sciences & 
      Research, Coimbatore, Tamil Nadu.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (Antineoplastic Agents)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Bortezomib/*therapeutic use
MH  - Female
MH  - Humans
MH  - Multiple Myeloma/*drug therapy
EDAT- 2016/10/21 06:00
MHDA- 2019/05/06 06:00
CRDT- 2016/10/21 06:00
PHST- 2016/10/21 06:00 [pubmed]
PHST- 2019/05/06 06:00 [medline]
PHST- 2016/10/21 06:00 [entrez]
PST - ppublish
SO  - J Assoc Physicians India. 2016 Aug;64(8):97-98.